CN109400684B - 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 - Google Patents
一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 Download PDFInfo
- Publication number
- CN109400684B CN109400684B CN201811361075.7A CN201811361075A CN109400684B CN 109400684 B CN109400684 B CN 109400684B CN 201811361075 A CN201811361075 A CN 201811361075A CN 109400684 B CN109400684 B CN 109400684B
- Authority
- CN
- China
- Prior art keywords
- pedv
- rbd
- monoclonal antibodies
- linear
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 title claims abstract description 97
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 20
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 20
- 239000012634 fragment Substances 0.000 abstract description 16
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 238000002965 ELISA Methods 0.000 abstract description 7
- 230000003053 immunization Effects 0.000 abstract description 7
- 210000004899 c-terminal region Anatomy 0.000 abstract description 5
- 238000011725 BALB/c mouse Methods 0.000 abstract description 2
- 210000003527 eukaryotic cell Anatomy 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- 230000006798 recombination Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000003259 recombinant expression Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200014005 rs1051338 Human genes 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001292005 Nidovirales Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- WFHRXJOZEXUKLV-IRXDYDNUSA-N Phe-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 WFHRXJOZEXUKLV-IRXDYDNUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- 101001001429 Homo sapiens Inositol monophosphatase 1 Proteins 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- 102100035679 Inositol monophosphatase 1 Human genes 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- PTDAGKJHZBGDKD-OEAJRASXSA-N Phe-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O PTDAGKJHZBGDKD-OEAJRASXSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- WFHYFCWBLSKEMS-KKUMJFAQSA-N Pro-Glu-Phe Chemical compound N([C@@H](CCC(=O)O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 WFHYFCWBLSKEMS-KKUMJFAQSA-N 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011999 immunoperoxidase monolayer assay Methods 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- GHZKGHQGPXBWSN-UHFFFAOYSA-N methyl(propan-2-yloxy)phosphinic acid Chemical compound CC(C)OP(C)(O)=O GHZKGHQGPXBWSN-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种PEDV S‑RBD线性B细胞表位及两株特异性识别单克隆抗体和应用,所述B细胞表位的氨基酸序列为:TIDLFGYP。利用纯化后PEDV S‑RBD重组蛋白免疫BALB/c小鼠,获得单克隆抗体;利用IPMA鉴定其中两株单克隆抗体可特异性识别PEDV;利用真核细胞HEK‑293T重组表达PEDV S‑RBD重组蛋白不同片段,通过Dot‑blot鉴定获得的两株单克隆抗体特异性识别PEDV S‑RBD C端区域;利用ELISA进一步鉴定PEDV S‑RBD C端区域合成多肽,鉴定获得的两株单克隆抗体特异性识别序列为TIDLFGYP的线性B细胞表位。
Description
技术领域
本发明涉及病毒学、分子生物学和免疫学领域,特别是涉及猪流行性腹泻病毒(porcine epidemic diarrhea virus,PEDV)纤突糖蛋白(spike glycoprotein,S)受体结合区(receptor-binding domain,RBD)线性B细胞表位及两株特异性识别单克隆抗体和应用。
背景技术
猪流行性腹泻(porcine epidemic diarrhea,PED)是由猪流行性腹泻病毒(PEDvirus,PEDV)引起的一种高度接触性猪肠道传染病,以发病猪呕吐、水样腹泻、脱水为主要特征。PED对各年龄阶段的猪都会造成影响,尤其对7日龄以内的哺乳仔猪具有高致死性,病死率高达100%。PED造成了我国养猪业巨大的经济损失,已成为制约我国养猪业健康发展的传染病之一。PEDV是一种具有囊膜的单股正链RNA病毒,属于套式病毒目(Nidovirales)冠状病毒科(Coronaviridae)α-型冠状病毒属(Alphacoronavirus),具有冠状病毒特征性的囊膜“纤突”(spike)结构。其中,PEDV纤突糖蛋白(spike glycoprotein,S)第505位氨基酸至第629位氨基酸为该病毒受体结合区(receptor binding domain,RBD),参与病毒结合宿主细胞表面受体进而入侵宿主细胞等关键过程,发挥着重要的致病和免疫学功能。然而,对于PEDV S-RBD抗原表位鉴定及其免疫识别等问题尚有待全面解决。
发明内容
针对现有研究的不足,本发明的目的是提供一种PEDV S-RBD线性B细胞表位,并提供特异性识别该表位的单克隆抗体。为鉴定本发明线性B细胞表位和两株单克隆抗体具有免疫学功能,利用所述单克隆抗体分别对含有该线性B细胞表位的多肽、蛋白、PEDV进行识别,结果表明所述PEDV S-RBD线性B细胞表位可被特异性识别。
为了实现上述目的,本发明所采用的技术方案是:
一种PEDV S-RBD线性B细胞表位,其氨基酸序列为:TIDLFGYP。
特异性识别PEDV S-RBD线性B细胞表位的两株单克隆抗体4D8F10和6F3E3,其特征在于,特异性识别含有PEDV S-RBD线性B细胞表位序列的多肽、蛋白及PEDV。
一种PEDV S-RBD线性B细胞表位在制备PED及PEDV诊断试剂或药物中的应用。
编码PEDV S-RBD线性B细胞表位的核苷酸序列。
所述核苷酸序列为ACCATAGATCTTTTTGGTTACCCT。
任何对所述核苷酸序列的优化。
本发明利用果蝇胚胎S2细胞表达系统表达PEDV S-RBD重组蛋白,经金属镍亲和层析和凝胶过滤层析两步纯化步骤获得高纯度,具有生物学活性和免疫原性的目的蛋白用于后续研究。
本发明利用纯化后PEDV S-RBD重组蛋白免疫BALB/c小鼠,获得单克隆抗体;利用免疫过氧化物酶单层细胞试验(immunoperoxidase monolayer assay,IPMA)鉴定其中两株单克隆抗体4D8F10和6F3E3可特异性识别PEDV;利用真核细胞HEK-293T重组表达PEDV S-RBD重组蛋白不同片段,通过Dot-blot鉴定获得的两株单克隆抗体特异性识别PEDV S-RBDC端区域,序列为TSLLASACTIDLFGYP;利用酶联免疫吸附试验(enzyme-linked
immunosorbent assay,ELISA)进一步鉴定PEDV S-RBD C端区域合成多肽,鉴定获得的两株单克隆抗体特异性识别序列为TIDLFGYP的线性B细胞表位。
本发明有益效果:
1、本发明综合利用病毒学、分子生物学和免疫学等技术,鉴定了一种PEDV S-RBD的全新线性B细胞表位,利用本发明制备的两株单克隆抗体对含有PEDV S-RBD线性B细胞表位的多肽、蛋白、PEDV进行识别,表明该PEDV S-RBD线性B细胞表位可被特异性识别;
2、本发明鉴定的PEDV S-RBD线性B细胞表位丰富了PEDV S-RBD免疫学功能,为后续研究S蛋白抗原漂移提供参考,可应用于抗病毒药物研发;
3、本发明制备的两株单克隆抗体可特异识别PEDV,可为PED及PEDV鉴别诊断提供新的工具。
附图说明
图1是PEDV S-RBD PCR产物及鉴定结果。
图中,A:1:PCR产物,M:DL 2000DNA marker;B:1-3:PCR鉴定产物,4:空载质粒对照,M:DL 2000DNA marker。
图2是PEDV S-RBD重组表达Western blot鉴定结果。
图中,M:蛋白marker,1:PEDV S-RBD。
图3是PEDV S-RBD重组蛋白纯化及鉴定结果。
图中,280nm吸光度下17.8mL洗脱峰为目的蛋白;M:蛋白marker,1:非还原条件下PEDV S-RBD重组蛋白,2:还原条件下PEDV S-RBD重组蛋白,3:经去糖基化后PEDV S-RBD重组蛋白。
图4是PEDV免疫阳性血清鉴定PEDV S-RBD重组蛋白。
图中,M:蛋白marker,1:PEDV免疫阳性血清鉴定PEDV S-RBD重组蛋白。
图5是IMPA鉴定制备的PEDV S-RBD单克隆抗体。
图中,A:单克隆抗体4D8F10杂交瘤细胞上清,B:单克隆抗体6F3E3杂交瘤细胞上清,C:PEDV免疫阳性血清,D:阴性杂交瘤细胞上清。
图6是Dot-blot鉴定制备的PEDV S-RBD单克隆抗体识别的PEDV S-RBD片段。
图7是ELISA鉴定制备的PEDV S-RBD单克隆抗体识别的PEDV S-RBD线性B细胞表位。
具体实施方式
以下结合实施例对本发明的具体实施方式作进一步详细说明。
实施例1.PEDV S-RBD重组蛋白构建、表达、纯化与鉴定
1.1PEDV S-RBD真核表达载体构建
将PEDV CH/HNXC毒株S-RBD基因序列交由生工生物工程(上海)股份有限公司进行密码子优化合成作为PCR模板,以S505-629F(上游引物):5’-GGAAGATCTCCATCGTTCAACGATCACAGCT-3’(SEQ ID NO.1)、S505-629R(下游引物):5’-CGACGCGTGGTGATCAGCTCTCCCTTTGTG-3’(SEQ ID NO.2)为引物PCR扩增S-RBD cDNA,在PCR产物两端分别引入Bgl II和Mlu I酶切位点(下划线为酶切位点)。PCR反应体系为50μL:5×HF缓冲液10μL,S505-629F、S505-629R各2.5μL(10μM),2.5mM dNTPs 4μL,Phusion DNA聚合酶1μL(2U/μL),模板0.5μL(50ng),加ddH2O至50μL。PCR反应条件为:95℃预变性2min;95℃变性30s,59℃退火30s,72℃延伸2min 30s,35个循环;72℃再延伸10min,16℃5min结束反应。PCR目的产物经1%琼脂糖凝胶电泳鉴定并回收,如图1A结果显示,表明扩增出了与预期大小相同的特异性核酸条带。经Bgl II和Mlu I双酶切获得的目的片段插入表达载体pMT/BiP/V5-His A(美国Invitrogen公司)相应酶切位点,将重组pMT/BiP/S-RBD-His表达载体转化大肠杆菌克隆菌株Trans5α感受态细胞(北京全式金生物技术有限公司),挑取单克隆经PCR鉴定阳性后交由生工生物工程(上海)股份有限公司鉴定。如图1B结果显示扩增出了与预期大小相同的条带,表明PEDV S-RBD基因已定向插入到表达载体中,获得重组了表达质粒pMT/BiP/S-RBD-His。
1.2 PEDV S-RBD重组蛋白表达及Western blot检测
将鉴定正确的pMT/BiP/S-RBD-His重组表达载体与pCoBlast筛选载体按操作说明使用II Reagent阳离子脂质体转染试剂共转染果蝇胚胎Drosophila Schneider2(S2)细胞(美国Invitrogen公司),经25μg/mL杀稻瘟菌素(blasticidin,美国Invitrogen公司)筛选获得稳定转染细胞株。使用无血清昆虫细胞培养基(serum-free medium,SFM)Sf-900II(美国Invitrogen公司)扩大培养稳定转染的S2细胞株,待细胞密度达到3~6×106个/mL时加入终浓度0.75mM的CuSO4溶液进行诱导表达。诱导5d后离心(4℃,2000rpm,10min;4℃,10000rpm,30min)收取诱导表达上清液。取部分上清液经15%SDS-PAGE后,将电泳分离的蛋白转到聚偏二氟乙烯膜(PVDF,美国Millipore公司),依次加入小鼠抗组氨酸标签抗体和辣根过氧化物酶标记的羊抗鼠IgG抗体(武汉三鹰生物技术有限公司)进行孵育,使用超敏化学发光(ECL)试剂(北京索莱宝科技有限公司)显色检测目的蛋白。因目的蛋白融合有组氨酸标签,取诱导表达产物经抗组氨酸标签Western blot检测,在与预期大小相同15kDa左右处出现一条明显的特征蛋白质表达带,表明目的蛋白表达(图2)。
1.3 PEDV S-RBD重组蛋白纯化及鉴定
取1L诱导表达上清液,使用0.22μm滤膜(美国Millipore公司)过滤后,依次使用美国GE公司HisTrap excel预装柱、Superdex 200increase 10/300GL预装柱对诱导表达上清液进行金属镍亲和层析和凝胶过滤层析纯化。以20mM Tris-HCl(pH 7.6),150mM NaCl为纯化洗脱液,收集的纯化蛋白分别在还原(加β-巯基乙醇)和非还原(不加β-巯基乙醇)条件下进行15%SDS-PAGE检测;同时取部分纯化蛋白使用去糖基化酶(PNGase F,美国NewEngland Biolabs公司)进行处理,进行15%SDS-PAGE检测目的蛋白糖基化情况。另取纯化蛋白上清液经15%SDS-PAGE后,将电泳分离的蛋白转到PVDF膜,依次加入PEDV免疫小鼠阳性血清和辣根过氧化物酶标记的羊抗鼠IgG抗体进行孵育,使用ECL试剂显色检测目的蛋白。
结果表明,经纯化后PEDV S-RBD目的蛋白在凝胶过滤层析的洗脱峰(17.8mL)单一,纯度高达99%;SDS-PAGE显示目的蛋白在非还原和还原条件下及经去糖基化处理后条带发生变化,表明目的蛋白含有二硫键和糖基化修饰,与预期相符(图3)。使用PEDV免疫阳性血清检测,PEDV S-RBD重组蛋白可被特异性识别(图4),证明重组蛋白具有与PEDV相当的免疫原性。
实施例2.PEDV S-RBD重组蛋白单克隆抗体制备与鉴定
2.1 PEDV S-RBD重组蛋白单克隆抗体制备
选取5只无特定病原体(SPF)级6-8周龄BALB/c雌性小鼠,首次免疫时按50μg PEDVS-RBD重组蛋白(添加有美国Sigma公司弗氏完全佐剂)/100μL·只小鼠进行免疫。间隔3周后,添加弗氏不完全佐剂(美国Sigma公司)按首次免疫剂量免疫。间隔3周后,进行第三次免疫,步骤同第二次免疫。间隔两周后,进行第四次免疫,步骤同第三次免疫。超级免疫在细胞融合前3-4d进行,超级免疫时直接进行腹腔注射,按100μg PEDV S-RBD重组蛋白/100μL·只免疫(不添加佐剂)。取超级免疫后小鼠脾细胞与小鼠骨髓瘤SP2/0细胞按照1:5混合在一起,添加50%PEG1500(美国Sigma公司)进行融合。细胞融合10d后,融合的杂交瘤细胞形成克隆并且占据一定面积的细胞培养孔。经免疫过氧化物酶单层细胞试验(IPMA)初步鉴定后,将阳性杂交瘤细胞克隆转移到24孔细胞培养板中,通过有限稀释法进行单克隆化,确保获得稳定分泌单克隆抗体的杂交瘤细胞株。经IPMA鉴定单克隆阳性孔、收集细胞上清并将有效的阳性单克隆进行小鼠腹水制备,备用。
2.2免疫过氧化物酶单层细胞试验(IPMA)鉴定PEDV S-RBD单克隆抗体
以200TCID50PEDV CH/hubei/2016毒株接种非洲绿猴肾上皮Vero易感细胞单层覆盖的96孔细胞板,当细胞出现明显病变时用含3%(v/v)H2O2的甲醇固定细胞制备IPMA反应板。将杂交瘤细胞上清液按50μL/孔加至IPMA反应板,以PEDV免疫阳性血清和阴性杂交瘤细胞上清液作对照,再加入辣根过氧化物酶标记的羊抗鼠IgG抗体作为二抗,3-氨基-9-乙基咔唑(AEC,北京索莱宝科技有限公司)为显色底物,倒置显微镜下观察分析细胞染色情况。
经IPMA鉴定,如图5A和图5B制备的单克隆抗体4D8F10和6F3E3对感染有PEDV的细胞有清晰细胞质染色,这与PEDV免疫阳性血清染色情况类似(图5C),而阴性杂交瘤细胞上清不能染色(图5D),表明这两株单克隆抗体可特异识别PEDV CH/hubei/2016毒株。
实施例3.Dot-blot鉴定单克隆抗体识别PEDV S-RBD区域
3.1 PEDV S-RBD片段重组表达载体构建
表1.PEDV S-RBD截短片段引物序列
注:下划线表示引入的限制性内切酶切割位点。
以PEDV CH/HNXC毒株S-RBD cDNA作为PCR模板,以表1中引物PCR扩增PEDV S-RBD不同片段基因,在PCR产物两端分别引入EcoR I和Nco I酶切位点。PCR目的产物经1%琼脂糖凝胶电泳鉴定并回收,经双酶切获得的目的片段插入表达载体pFuse-hIgG1-Fc2载体(美国InvivoGen公司)相应酶切位点,将重组表达载体转化大肠杆菌克隆菌株JM109感受态细胞(TaKaRa公司),挑取单克隆经PCR鉴定阳性后交由生工生物工程(上海)股份有限公司鉴定。
3.2 PEDV S-RBD片段重组表达
将鉴定正确的重组表达载体转染人胚肾上皮细胞293T(HEK-293T)。扩大培养转染细胞,转染48h后离心收取细胞上清液。上清液经Protein A亲和层析纯化后,在硝酸纤维素膜(美国Millipore公司)上点印重组表达的不同PEDV S-RBD片段,以人源IgG1型抗体的Fc区段为对照,依次加入兔抗人源IgG Fc抗体和辣根过氧化物酶标记的羊抗兔IgG抗体进行孵育,使用ECL试剂显色检测目的蛋白。
如图6结果显示,同人源IgG1型抗体的Fc区段(hFc)阳性对照一样,PEDV S-RBD不同片段均有表达(呈现黑色颜色反应阳性点)。
3.3 Dot-blot鉴定PEDV S-RBD单克隆抗体识别区域
确认目的蛋白表达后,在硝酸纤维素膜上点印重组表达的不同PEDV S-RBD片段。自然干燥后,将印迹膜37℃封闭1h;依次加入制备的PEDV S-RBD单克隆抗体4D8F10和6F3E3、辣根过氧化物酶标记的羊抗鼠IgG抗体进行孵育。使用ECL试剂显色判定,以阳性点呈现黑色颜色反应,阴性点不出现颜色反应进行判定。
如图6结果显示,序列为TSLLASACTIDLFGYP的C-C1区域可被制备的单克隆抗体4D8F10和6F3E3特异性识别。
实施例4.酶联免疫吸附试验(ELISA)鉴定PEDV S-RBD单克隆抗体识别的线性B细胞表位
根据上一步鉴定的区域,分别通过N端截短和C端截短合成图7中多肽。合成多肽经鉴定序列正确,纯度均可达到95%以上。使用DMSO溶解合成多肽,加入0.01M盐酸将pH值调至4-5;加入含1-(3-二甲氨基丙基)-3-乙基碳二亚胺(EDC,购自美国Thermo公司)反应液,室温反应15min;稀释牛血清白蛋白(BSA),逐滴加入到合成多肽反应液中,混匀后室温反应2h,形成BSA-多肽备用。以5mg/mL浓度将BSA-多肽按100μL/孔包被96孔酶标板,4℃孵育过夜后,加入含5%(w/v)脱脂奶粉封闭液封闭。加入制备的PEDV S-RBD单克隆抗体4D8F10和6F3E3的杂交瘤细胞上清液(1:100稀释,每孔加100μL),37℃孵育1h,加入辣根过氧化物酶标记的羊抗鼠IgG抗体和3,3',5,5'-四甲基联苯胺(TMB,美国Sigma公司)室温避光反应5min,使用2M浓硫酸终止反应,并读取450nm的吸光值,检测PEDV S-RBD单克隆抗体4D8F10和6F3E3与酶标板上BSA-多肽的结合;同时以不结合小鼠IgG的BSA为阴性对照。样品OD450值与阴性对照OD450值的比值大于或等于2.2时可判定为阳性,其它则为阴性。
经ELISA鉴定,单克隆抗体4D8F10和6F3E3与N端截短片段结合OD450值与阴性对照OD450值的比值均大于2.2,表明单克隆抗体4D8F10和6F3E3均可以和N端截短至T8P(TIDLFGYP)的片段结合;而单克隆抗体4D8F10和6F3E3仅与C端截短片段中T16P和T15Y结合OD450值与阴性对照OD450值的比值大于2.2,表明单克隆抗体4D8F10和6F3E3仅能与C端截短片段中T16P和T15Y结合,说明这两株单克隆抗体结合的位点位于T16P的C端。综上所述,制备的2株单克隆抗体4D8F10和6F3E3识别的B细胞表位序列为TIDLFGYP(SEQ ID NO.24),为线性表位(图7,图7为三次重复实验结果的平均值),其编码序列为ACCATAGATCTTTTTGGTTACCCT(SEQ ID NO.25)。
以上所述仅为本发明较佳的实施例,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
序列表
<110> 河南省农业科学院
<120> 一种PEDV S-RBD线性B细胞表位及两株特异性识别单克隆抗体和应用
<160> 25
<170> SIPOSequenceListing 1.0
<210> 1
<211> 31
<212> DNA
<213> 人工序列()
<400> 1
ggaagatctc catcgttcaa cgatcacagc t 31
<210> 2
<211> 30
<212> DNA
<213> 人工序列()
<400> 2
cgacgcgtgg tgatcagctc tccctttgtg 30
<210> 3
<211> 28
<212> DNA
<213> 人工序列()
<400> 3
ccggaattcg ccctccttca acgaccat 28
<210> 4
<211> 29
<212> DNA
<213> 人工序列()
<400> 4
catgccatgg catcctggga cttgctcac 29
<210> 5
<211> 28
<212> DNA
<213> 人工序列()
<400> 5
ccggaattcg gtgagcaagt cccaggat 28
<210> 6
<211> 30
<212> DNA
<213> 人工序列()
<400> 6
catgccatgg ctgtaatgag ctcccccttt 30
<210> 7
<211> 28
<212> DNA
<213> 人工序列()
<400> 7
ccggaattcg ccctccttca acgaccat 28
<210> 8
<211> 29
<212> DNA
<213> 人工序列()
<400> 8
catgccatgg ccacgcaaaa ggaagagaa 29
<210> 9
<211> 28
<212> DNA
<213> 人工序列()
<400> 9
ccggaattcg atcaacggat tctcttcc 28
<210> 10
<211> 29
<212> DNA
<213> 人工序列()
<400> 10
catgccatgg catcctggga cttgctcac 29
<210> 11
<211> 28
<212> DNA
<213> 人工序列()
<400> 11
ccggaattcg gtgagcaagt cccaggat 28
<210> 12
<211> 29
<212> DNA
<213> 人工序列()
<400> 12
catgccatgg ctgtgcaggc gctggccag 29
<210> 13
<211> 28
<212> DNA
<213> 人工序列()
<400> 13
ccggaattcg actagcctgc tggccagc 28
<210> 14
<211> 30
<212> DNA
<213> 人工序列()
<400> 14
catgccatgg ctgtaatgag ctcccccttt 30
<210> 15
<211> 56
<212> DNA
<213> 人工序列()
<400> 15
aattcgacta gcctgctggc cagcgcctgc acaattgacc tgttcggcta ccctgc 56
<210> 16
<211> 56
<212> DNA
<213> 人工序列()
<400> 16
catggcaggg tagccgaaca ggtcaattgt gcaggcgctg gccagcaggc tagtcg 56
<210> 17
<211> 56
<212> DNA
<213> 人工序列()
<400> 17
aattcgttcg gctaccctga gttcgggtcc ggagtgaagt ttaccagcct ctacgc 56
<210> 18
<211> 56
<212> DNA
<213> 人工序列()
<400> 18
catggcgtag aggctggtaa acttcactcc ggacccgaac tcagggtagc cgaacg 56
<210> 19
<211> 50
<212> DNA
<213> 人工序列()
<400> 19
aattcgacca gcctctactt ccagtttaca aagggggagc tcattacagc 50
<210> 20
<211> 50
<212> DNA
<213> 人工序列()
<400> 20
catggctgta atgagctccc cctttgtaaa ctggaagtag aggctggtcg 50
<210> 21
<211> 16
<212> PRT
<213> 猪流行性腹泻病毒(Porcine Epidemic Diarrhea Virus)
<400> 21
Thr Ser Leu Leu Ala Ser Ala Cys Thr Ile Asp Leu Phe Gly Tyr Pro
1 5 10 15
<210> 22
<211> 16
<212> PRT
<213> 猪流行性腹泻病毒(Porcine Epidemic Diarrhea Virus)
<400> 22
Phe Gly Tyr Pro Glu Phe Gly Ser Gly Val Lys Phe Thr Ser Leu Tyr
1 5 10 15
<210> 23
<211> 14
<212> PRT
<213> 猪流行性腹泻病毒(Porcine Epidemic Diarrhea Virus)
<400> 23
Thr Ser Leu Tyr Phe Gln Phe Thr Lys Gly Glu Leu Ile Thr
1 5 10
<210> 24
<211> 8
<212> PRT
<213> 猪流行性腹泻病毒(Porcine Epidemic Diarrhea Virus)
<400> 24
Thr Ile Asp Leu Phe Gly Tyr Pro
1 5
<210> 25
<211> 24
<212> DNA
<213> 人工序列()
<400> 25
accatagatc tttttggtta ccct 24
Claims (4)
1.一种PEDV S-RBD线性B细胞表位肽,其特征在于,所述表位肽的氨基酸序列为:TIDLFGYP。
2.一种权利要求1所述的PEDV S-RBD线性B细胞表位肽在制备PEDV诊断试剂或药物中的应用。
3.编码如权利要求1所述PEDV S-RBD线性B细胞表位肽的核苷酸。
4.根据权利要求3所述的编码PEDV S-RBD线性B细胞表位肽的核苷酸,其特征在于,所述核苷酸的序列为ACCATAGATCTTTTTGGTTACCCT。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811361075.7A CN109400684B (zh) | 2018-11-15 | 2018-11-15 | 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811361075.7A CN109400684B (zh) | 2018-11-15 | 2018-11-15 | 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109400684A CN109400684A (zh) | 2019-03-01 |
CN109400684B true CN109400684B (zh) | 2021-08-06 |
Family
ID=65473536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811361075.7A Active CN109400684B (zh) | 2018-11-15 | 2018-11-15 | 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109400684B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111939250B (zh) * | 2020-08-17 | 2022-07-29 | 郑州大学 | 一种预防covid-19的疫苗及其制备方法 |
CN115261331B (zh) * | 2022-07-07 | 2024-05-10 | 河南省农业科学院 | 一株抗pedv s蛋白的单克隆抗体及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103088039A (zh) * | 2013-01-14 | 2013-05-08 | 广东大华农动物保健品股份有限公司 | 一种猪流行性腹泻病毒s基因抗原表位的扩增方法 |
CN103740649A (zh) * | 2013-12-06 | 2014-04-23 | 中国农业科学院哈尔滨兽医研究所 | 抗蓝舌病病毒血清16型vp2蛋白单克隆抗体btv16-2b4及其识别的b细胞表位和应用 |
WO2017068352A1 (en) * | 2015-10-22 | 2017-04-27 | The Royal Veterinary College | Methods |
CN107921115A (zh) * | 2015-05-15 | 2018-04-17 | 瑞宝基因股份有限公司 | 新颖杆状病毒载体及使用方法 |
CN108219000A (zh) * | 2018-01-17 | 2018-06-29 | 北京市农林科学院 | 一种pedv保护性抗原蛋白及其在乳酸菌中表达的方法 |
-
2018
- 2018-11-15 CN CN201811361075.7A patent/CN109400684B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103088039A (zh) * | 2013-01-14 | 2013-05-08 | 广东大华农动物保健品股份有限公司 | 一种猪流行性腹泻病毒s基因抗原表位的扩增方法 |
CN103740649A (zh) * | 2013-12-06 | 2014-04-23 | 中国农业科学院哈尔滨兽医研究所 | 抗蓝舌病病毒血清16型vp2蛋白单克隆抗体btv16-2b4及其识别的b细胞表位和应用 |
CN107921115A (zh) * | 2015-05-15 | 2018-04-17 | 瑞宝基因股份有限公司 | 新颖杆状病毒载体及使用方法 |
WO2017068352A1 (en) * | 2015-10-22 | 2017-04-27 | The Royal Veterinary College | Methods |
CN108219000A (zh) * | 2018-01-17 | 2018-06-29 | 北京市农林科学院 | 一种pedv保护性抗原蛋白及其在乳酸菌中表达的方法 |
Non-Patent Citations (4)
Title |
---|
Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies;Chunhua Li et al.;《Journal of Virology》;20170630;第91卷(第12期);摘要,第4页第1-4段,图2-4 * |
Chunhua Li et al..Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies.《Journal of Virology》.2017,第91卷(第12期), * |
Identification of a novel linear B-cell epitope within the collagenase equivalent domain of porcine epidemic diarrhea virus spike glycoprotein;Yan-gang Sun et al.;《Virus Research》;20190406;第266卷;第34-42页 * |
华南地区猪流行性腹泻病毒的分离鉴定及其S基因抗原表位片段的遗传变异分析;田野等;《中国兽医杂志》;20131231;第49卷(第5期);第3-5、8页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109400684A (zh) | 2019-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109796531B (zh) | 猪Delta冠状病毒N蛋白单克隆抗体及其抗原表位和应用 | |
UA108064C2 (uk) | Вектор експресії, що містить молекулу нуклеїнової кислоти, яка кодує ізольований тимусний стромальний лімфопоетичний білок (tslp) або його антигенний фрагмент | |
CN109400684B (zh) | 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 | |
CN109863164B (zh) | 辣根过氧化物酶-igg融合蛋白的制备 | |
CN107987164B (zh) | 雌激素受体ER-α36抗原多肽及其单克隆抗体 | |
CN113527475B (zh) | 一种分泌鸭新型呼肠孤病毒σC蛋白单抗的杂交瘤细胞、单抗及应用 | |
CN111333709A (zh) | 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用 | |
CN114276445A (zh) | 轮状病毒重组蛋白特异性抗体、质粒载体及方法 | |
US20210277147A1 (en) | Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof | |
WO2018199538A1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질과 C4bp 올리고머화 도메인이 연결된 융합 단백질 및 이의 용도 | |
WO2018212468A1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질에 마우스 항체 유래 Fc 도메인이 연결된 융합 단백질 및 이의 용도 | |
CN113603786B (zh) | 特异性结合SARS-CoV-2 S蛋白和N蛋白的双特异性抗体 | |
CN113683692B (zh) | SARS-CoV-2 N蛋白抗体及其应用 | |
CN111763255B (zh) | 一种经基因修饰的vegfa蛋白及其单克隆抗体与应用 | |
KR101972894B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도 | |
CN113527446A (zh) | 一种MERS-CoV S-RBD线性B细胞表位及其特异性识别单克隆抗体和应用 | |
KR20230038903A (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 폴돈 도메인이 연결된 융합 단백질 및 이의 용도 | |
CN112063591B (zh) | 分泌抗Spondin1单克隆抗体杂交瘤细胞株及其单抗、应用 | |
CN110054675B (zh) | 免疫原性多肽以及抗ttc36抗体cp4-3及应用 | |
Rouis et al. | Inhibition of potato virus Y NIa activity: preparation of monoclonal antibody directed against PVY NI protein that inhibits cleavage of PVY polyprotein | |
KR102259974B1 (ko) | 재조합 항원을 이용하여 목적 항원 특이적인 항체를 제조하는 방법 | |
CN108285903B (zh) | 一种特异性刺激抗原的制备方法 | |
CN112250767B (zh) | 一种结合Strep-Tag II标签的抗体及其应用 | |
CN114317453A (zh) | 一种分泌胰岛素单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 | |
CN118255877A (zh) | 一种抗猪流行性腹泻病毒s1蛋白的单克隆抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |